TMS Geno-Serum

Genetic

Report in 48Hrs

At Home

No Fasting Required

Details

Tandem MS-based genetic panel.

₹6,512₹9,303

30% OFF

TMS Geno-Serum Test Information Guide

Section 1: Why is it done?
- Test Description: TMS Geno-Serum is a comprehensive pharmacogenomic test that analyzes genetic variations affecting medication metabolism and treatment response. It combines serum biomarkers with genetic profiling to predict individual drug efficacy and adverse event risk.
- Primary Indications: Personalized medication selection for psychiatric disorders, pain management, and chronic conditions; assessment of treatment response variability; prediction of medication side effects; optimization of drug dosing strategies
- When Test is Performed: Prior to initiating new medication regimens; when patients experience suboptimal medication response; before dose adjustments; when adverse drug events occur; during comprehensive medication management evaluations; in cases of polypharmacy requiring optimization
Section 2: Normal Range
- Reference Ranges: Results are reported as genotype classifications (CYP450 enzyme activity levels: Poor Metabolizer, Intermediate Metabolizer, Extensive Metabolizer, Ultra-Rapid Metabolizer); serum biomarkers measured in standard units (ng/mL, pg/mL, μmol/L depending on specific biomarker)
- Normal Interpretation: Extensive Metabolizer status with biomarkers within established reference intervals indicates standard medication metabolism; patient likely to respond predictably to standard drug dosing; lower risk of accumulation or inadequate drug levels
- Abnormal Interpretation: Poor Metabolizer status indicates significantly reduced drug metabolism requiring dose reduction; Ultra-Rapid Metabolizer indicates accelerated metabolism possibly requiring higher doses; Intermediate Metabolizer reflects variable metabolism patterns; Elevated or depressed serum biomarkers may indicate organ dysfunction affecting drug metabolism
- Units of Measurement: Genotype reports use categorical phenotypes (PM/IM/EM/URM); serum biomarkers reported in conventional laboratory units; metabolic activity index reported as percentage relative to normal
Section 3: Interpretation
- Result Value Interpretation: Poor Metabolizer (PM) - Drug accumulation risk, recommend 25-50% dose reduction; Intermediate Metabolizer (IM) - Variable response, consider 25% dose reduction or increased monitoring; Extensive Metabolizer (EM) - Standard dosing typically appropriate; Ultra-Rapid Metabolizer (URM) - May require higher doses for therapeutic effect; substrate status indicates likelihood of drug-drug interactions
- Clinical Significance: Identifies genetic polymorphisms in cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP2C9, CYP3A4); predicts medication efficacy and toxicity risk; enables precision medicine approach; significantly improves treatment outcomes; reduces adverse events and emergency interventions
- Factors Affecting Results: Concurrent medications inducing or inhibiting enzyme activity; liver and kidney function status; age-related metabolic changes; disease states affecting metabolism; smoking and alcohol use; sample collection timing relative to medication administration; genetic ancestry variations
- Result Pattern Significance: Multiple gene abnormalities increase complexity of drug interactions; elevated inflammatory biomarkers may indicate compromised metabolism capacity; reduced biomarker levels may suggest organ dysfunction; combination of genetic and biochemical findings provides comprehensive metabolic profile
Section 4: Associated Organs
- Primary Organ Systems: Hepatic system (liver - primary site of cytochrome P450 enzyme production); renal system (kidneys - drug elimination pathway); central nervous system (target organ for psychotropic medications); gastrointestinal tract (initial drug metabolism site)
- Associated Medical Conditions: Major depressive disorder; anxiety disorders; bipolar disorder; attention-deficit hyperactivity disorder; chronic pain syndromes; post-traumatic stress disorder; obsessive-compulsive disorder; insomnia; substance use disorders; cardiovascular conditions requiring pharmacotherapy
- Diagnostic Applications: Identifies treatment-resistant psychiatric conditions requiring genetic assessment; determines suitability for specific antidepressants, antipsychotics, and anxiolytics; guides pain management medication selection; predicts response to cardiovascular medications; helps diagnose potential drug toxicity vs inadequate response
- Potential Complications of Abnormal Results: Serotonin syndrome from inadequate metabolism of serotonergic agents; neuroleptic malignant syndrome risk; hepatotoxicity from drug accumulation; renal failure from prolonged drug exposure; cardiovascular complications from QT prolongation; cognitive impairment; falls and injuries; organ damage from chronic medication toxicity
Section 5: Follow-up Tests
- Recommended Follow-up Testing: Comprehensive metabolic panel (liver and kidney function); serum medication levels (therapeutic drug monitoring); baseline psychiatric or pain scales; cardiovascular assessments as indicated; repeat pharmacogenomic testing if genetic factors suggest need for extended panel evaluation
- Further Investigations Based on Results: If Poor Metabolizer: liver function studies, consideration of hepatic imaging; If Ultra-Rapid Metabolizer: investigation of concurrent enzyme inducers; If abnormal biomarkers: imaging of liver and kidneys, specialist referral; If multiple gene variants: comprehensive drug interaction assessment with pharmacist consultation
- Monitoring Frequency: Initial assessment 2-4 weeks after medication adjustment; monthly follow-up for first 3 months of new regimen; quarterly monitoring during stable treatment; semi-annual comprehensive metabolic evaluations; annual reassessment unless clinical changes warrant sooner evaluation
- Complementary Tests: Genomic variants for other drug-metabolizing enzymes (Phase 2 enzymes); inflammatory markers (CRP, cytokine levels); brain imaging (fMRI, PET) for treatment-resistant conditions; genetic counseling for family implications; expanded pharmacogenomic panels for complex polypharmacy cases
Section 6: Fasting Required?
- Fasting Requirement: No - Fasting is not required for TMS Geno-Serum testing. The test can be performed at any time of day regardless of meal consumption. However, consistent timing of sample collection is beneficial for serum biomarker comparisons.
- Special Instructions: Continue all current medications as prescribed; do not alter medication timing on test day; maintain regular sleep-wake cycle; avoid excessive caffeine consumption 24 hours prior (caffeine may affect some biomarkers); stay well-hydrated; avoid strenuous exercise 24 hours before collection
- Medications to Continue: Take all prescribed medications on normal schedule; continue psychiatric medications, pain medications, and chronic condition treatments; do not discontinue or adjust dosages prior to testing; medication interactions are part of the assessment interpretation
- Patient Preparation Requirements: Bring photo identification and insurance card; provide complete medication list including dosages and frequencies; document over-the-counter drugs, supplements, and herbal products; inform phlebotomist of recent illnesses or infections; ensure adequate sleep (6-8 hours) previous night; arrive on time and remain seated 5 minutes before blood draw; relax to reduce adrenaline effects on biomarkers

How our test process works!